Using the microbiome to treat disease

BiomeBank is a clinical stage biotechnology company with a mission to treat and prevent disease by restoring gut microbial ecology.
Introducing BiomeBank (1:40)

Who are you?

I'm an investor

I want to learn more about BiomeBank and its microbiome drug development portfolio.

I'm a clinician

I want to know how microbiome-based therapies can help my patients.

Unique ecosystem based approach to drug development

The loss of gut microbial diversity represents a major health problem for humanity. Gut microbes perform many critical function for us and their loss can result in disease.

BiomeBank has developed a platform to tackle this global problem at scale. This centres on the ability to produce cultured, synthetic human microbiomes enriched with specific functions to target disease.

Our team of translational microbiome experts has now developed a breakthrough co-culturing platform that will allow us produce a range of efficacious microbiome therapies at scale. These new co-cultured therapies can be enriched for defined and patented disease specific functions and importantly are produced at a much lower cost than the current donor-derived treatments.

Our innovative microbial therapies contain an extensive and diverse community of human gut microbes. These microbial consortia treat disease by repopulating missing microbes and restoring lost function.

BiomeBank’s donor-derived microbiome therapy is the first such therapy approved world-wide and is used extensively to treat patients with C.difficile in hospitals throughout Australia and is being reformulated for an orphan disease indication for the US market.

“The gut microbiome is a complex ecosystem providing health benefits that are more than the sum of its parts. Much like a rainforest, losing some important elements can have a devastating effect on the functioning of the whole.

We are restoring health through the broad restoration of the gut microbial ecosystem.”

– Dr Sam Costello
Managing Director & Co-founder

We are a multidisciplinary team of research scientists and drug development experts who are at the forefront of microbiome research, looking to discover and develop microbiome-based therapies.

The translation of research into the development of innovative and life-saving microbiome-based therapies are further bolstered by BiomeBank’s partnership with world-leading biomedical research organisations. This includes RMIT University, Hudson Institute of Medical Research, and Hospital Networks globally.

BiomeBank's pioneering research has been published in these leading medical journals:

Be a Su-Poo-Hero!

Become a stool donor today and save someones life.

The gut microbiome is the community of organisms that live in your intestinal tract. In fact, trillions of microbes call the human gut home. Although one single microbe is harmless, vast communities of different species together carry important functions for maintaining health, similar to an organ. Loss of function can lead to chronic disease.

In recent years new technology has enabled scientists to culture and analyse the DNA of these complex communities. This has paved the way for new breakthroughs in the treatment of chronic disease where the traditional approach of drugs and surgeries are proving inadequate.

BiomeBank-Reading Microbiome